280 related articles for article (PubMed ID: 31908124)
1. Polypharmacy in schizophrenia.
Baandrup L
Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):183-192. PubMed ID: 31908124
[TBL] [Abstract][Full Text] [Related]
2. [Polypharmacy in schizophrenia].
Zink M; Englisch S; Meyer-Lindenberg A
Nervenarzt; 2011 Jul; 82(7):853-8. PubMed ID: 21165589
[TBL] [Abstract][Full Text] [Related]
3. [Optimizing the antipsychotic potency of olanzapine by augmentation--a critical review].
Zink M
Psychiatr Prax; 2006 Sep; 33(6):261-8. PubMed ID: 16929455
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations.
Lähteenvuo M; Tiihonen J
Drugs; 2021 Jul; 81(11):1273-1284. PubMed ID: 34196945
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders.
Thompson JV; Clark JM; Legge SE; Kadra G; Downs J; Walters JT; Hamshere ML; Hayes RD; Taylor D; MacCabe JH
J Psychopharmacol; 2016 May; 30(5):436-43. PubMed ID: 26905920
[TBL] [Abstract][Full Text] [Related]
6. Polypharmacy in schizophrenia.
Zink M; Englisch S; Meyer-Lindenberg A
Curr Opin Psychiatry; 2010 Mar; 23(2):103-11. PubMed ID: 20051861
[TBL] [Abstract][Full Text] [Related]
7. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.
Tiihonen J; Taipale H; Mehtälä J; Vattulainen P; Correll CU; Tanskanen A
JAMA Psychiatry; 2019 May; 76(5):499-507. PubMed ID: 30785608
[TBL] [Abstract][Full Text] [Related]
8. Maintenance phase treatment of psychotic disorders in outpatients from Serbia - focus on long-term benzodiazepine use.
Marić NP; Andrić Petrović S; Jerotić S; Ristić I; Savić B; Zebić M; Vuković V; Britvić D; Golubović O; Jakšić M; Jevđić K; Kolašinac Z; Lalović N; Mirković Ilić J; Nikolić S; Paunović Č; Pavlović Z; Pejović Nikolić S; Perović V; Popović J; Ranđić Avakumović V; Stojanović S; Tatarević M; Živković I; Voskresenski T; Jovanović N
Int J Psychiatry Clin Pract; 2020 Sep; 24(3):315-321. PubMed ID: 32459564
[No Abstract] [Full Text] [Related]
9. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia.
Tiihonen J; Suokas JT; Suvisaari JM; Haukka J; Korhonen P
Arch Gen Psychiatry; 2012 May; 69(5):476-83. PubMed ID: 22566579
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study.
Baandrup L; Gasse C; Jensen VD; Glenthoj BY; Nordentoft M; Lublin H; Fink-Jensen A; Lindhardt A; Mortensen PB
J Clin Psychiatry; 2010 Feb; 71(2):103-8. PubMed ID: 19895781
[TBL] [Abstract][Full Text] [Related]
11. Patterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review & assessment service-national patient sample.
Park SC; Lee MS; Kang SG; Lee SH
J Korean Med Sci; 2014 May; 29(5):719-28. PubMed ID: 24851031
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic polypharmacy in schizophrenia: benefits and risks.
Barnes TR; Paton C
CNS Drugs; 2011 May; 25(5):383-99. PubMed ID: 21476610
[TBL] [Abstract][Full Text] [Related]
13. Adverse Drug Reactions Associated with Antipsychotics, Antidepressants, Mood Stabilizers, and Stimulants.
Givens CJ
Nurs Clin North Am; 2016 Jun; 51(2):309-21. PubMed ID: 27229284
[TBL] [Abstract][Full Text] [Related]
14. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
15. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
Constantine RJ; Andel R; McPherson M; Tandon R
Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory processes linked to major depression and schizophrenic disorders and the effects of polypharmacy in psychiatry: evidence from a longitudinal study of 279 patients under therapy.
Stassen HH; Bachmann S; Bridler R; Cattapan K; Herzig D; Schneeberger A; Seifritz E
Eur Arch Psychiatry Clin Neurosci; 2021 Apr; 271(3):507-520. PubMed ID: 32696276
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion?
Lin SK
Int J Neuropsychopharmacol; 2020 Feb; 23(2):125-131. PubMed ID: 31867671
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale.
Azorin JM; Simon N
Expert Opin Drug Metab Toxicol; 2020 Dec; 16(12):1175-1186. PubMed ID: 32930009
[TBL] [Abstract][Full Text] [Related]
19. Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment.
Längle G; Steinert T; Weiser P; Schepp W; Jaeger S; Pfiffner C; Frasch K; Eschweiler GW; Messer T; Croissant D; Becker T; Kilian R
Acta Psychiatr Scand; 2012 May; 125(5):372-81. PubMed ID: 22321029
[TBL] [Abstract][Full Text] [Related]
20. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia.
Fleischhacker WW; Uchida H
Int J Neuropsychopharmacol; 2014 Jul; 17(7):1083-93. PubMed ID: 22717078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
